Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147402 | 0.89 | TRPV1 (0.54) | P2RY1EPHX2TNFNOD2NOD1 | |
| SCHEMBL1147334 | 0.88 | FAAH (0.53) | P2RY1EPHX2TNFNOD2NOD1 | |
| SCHEMBL1147286 | 0.88 | MAPT (0.54) | P2RY1EPHX2TNFNOD2NOD1 | |
| SCHEMBL1147265 | 0.86 | P2RY1 (0.48) | P2RY1EPHX2TNFNOD2NOD1 | |
| SCHEMBL11888824 | 0.84 | ALDH1A1 (0.57) | P2RY1CHRM4KCNH2ACHEBCHE | |
| SCHEMBL1146555 | 0.83 | FAAH (0.65) | SMN1; SMN2 | |
| SCHEMBL1147256 | 0.81 | RAB9A (0.55) | HIF1AEPAS1TP53SMN1; SMN2 | |
| SCHEMBL12655774 | 0.81 | ACHE (0.75) | EPHX2ACHE | |
| SCHEMBL5946503 | 0.80 | P2RY1 (0.59) | P2RY1EPHX2TNFNOD2NOD1 | |
| SCHEMBL1147209 | 0.79 | CHRM4 (0.48) | P2RY1CHRM4ACHEBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | P2RY1 17/4885EPHX2 3415/4885TNF 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.